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Introduction
------------

Good antibiotic prescribing-which often means less prescribing-is of major concern to physicians nowadays, both because of high levels of antibiotic consumption in hospitals, and of the increasing prevalence of antimicrobial resistance, even if rates of methicillin-resistant *Staphylococcus aureus* have decreased recently in many European countries since the early 2000s. The principal objective of antibiotic prescribing is to ensure appropriate therapy when needed, while avoiding unnecessary or unduly prolonged therapy. Within this framework, obtaining adequate microbiological information is of paramount importance; unfortunately, such information is lacking in more than 50% of clinical situations where antibiotic therapy is prescribed, even in hospitalized patients. Whereas clinical information is usually sufficient to initiate empiric therapy, they lack accuracy to tailor subsequent therapy and decide on its duration. Physicians' decisions would be strengthened if they could get help from results of accurate biomarkers reflecting the diagnosis or evolution of the infectious processes. The field of infection-associated biomarkers has grown rapidly within the past few years and is still expanding; few of them, however, have gone through the hurdles of rigorous testing in the clinical arena to allow specifying their role in clinical practice.

An 18-member expert panel convened under the auspices of the Maurice Rapin Institute, a not-for-profit independent physicians' association (<http://www.institutmauricerapin.org>), to provide a state-of-the-art assessment of the currently available biomarkers and their potential role as an aid to the management of antibiotic therapy for acute infections. This report is a summary of their work and conclusions.

To frame the appraisal of the potential clinical role of biomarkers, the panel was asked to answer three formatted questions, as follows:

1\. Which are the currently available biomarkers of the host's response, those that are routinely available and which may contribute to the management of antibiotics in acute infections, and what are the limitations to the interpretation of their results in this context?

2\. What is the potential contribution of such biomarkers to the initial decision of antibiotic prescription, and does this vary according to the characteristics of infection (i.e., site of infection, comorbidities, mode of acquisition, severity of presentation)?

3\. When can biomarkers help make decisions to stop antibiotic therapy, and which factors mitigate their clinical use in this process?

The panel discussion was based on an analysis of the available literature through December 2012, after making the a priori decision to limit publications considered for answering questions 2 and 3 to clinical studies fulfilling the following criteria:

Having enrolled a minimum of a substantial number of patients (i.e., \>50 patients);

Performed within less than 15 years (i.e., published since 2000);

Pertaining to biomarkers available for routine testing in hospitals' laboratories.

The first part of this paper deals with the first question asked to the panel, and the second part deals with questions 2 and 3.

Currently available biomarkers of the host
==========================================

Definition and role of a host's biomarker
-----------------------------------------

Biomarkers from the host can be anatomical, physiological, biochemical (either circulating or membrane-bound), or molecular markers. The latter two categories are detected within a tissue or biological fluid (e.g., blood, cerebrospinal fluid, or urine) and their presence or absence, or over- vs. under-expression is the judgment criteria. Of note, more than 90% currently available biomarkers are used only within research program and have not been introduced within the field of clinical biology.

### Definitions

Currently accepted definitions for biomarkers have emerged from an expert panel driven by the U.S. National Institute of Health \[[@B1]\] and from regulatory definitions issued by the European Medicines Agency. A biomarker is "a biological characteristic, objectively measured (i.e., with acceptable accuracy and reproducibility) and used as an indicator for a physiological or pathological process, or of the activity of a medicine." According to the NIH panel \[[@B1],[@B2]\], biomarkers can be stratified in two categories (Table [1](#T1){ref-type="table"}): *prognostic markers*, allowing to stratify patients according to their individual risk of having a specified outcome, independently of therapy (or of the lack of therapy), and *predictive markers*, which allow to predict the potential benefit (efficacy) and/or the risks (toxicity) of a therapy according to the biomarker status (absent/present).

###### 

**Definition of biomarkers and subtypes according to the national institute of health**\[[@B1]\]

  **Denomination**    **Definition**
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biomarker           Biological characteristics objectively measured, and used as a marker either of a normal or pathological biological pathway, or of a pharmacological response to a specific intervention
  Biomarker type 0    Biological maker of the disease course, linked to a recognised clinical variable
  Biomarker type I    Biological marker reflecting the effects of a therapy, and linked to its mechanism of action
  Biomarker type II   Biological marker used as a surrogate endpoint, where changes in the biomarker levels are associated to a clinical benefit or to an increased risk.

In clinical practice, two types of biomarkers can be identified, which follow different development and validation pathways:

Those used independently from a specific therapy, as a diagnostic test, or for follow-up or prognosis, which will only be discussed in this paper from the viewpoint of infectious processes;

Those used as a companion to treatment, to select patients who may benefit from a specific therapy or used during follow-up of therapy as early predictors of efficacy or of treatment toxicity.

### The ideal biomarker in infectious diseases

Within the field of infectious diseases, a biomarker may be used for identifying a high risk group or predisposing condition, as an aid to identification of the disease, or to direct therapy and stratify patients according to their specific risk factors, and/or as an aid to therapeutic management in order to avoid relapse of infection. An ideal biomarker for infection would combine diagnostic, prognostic, and follow-up of therapy characteristics and should be easily and rapidly available for routine clinical use (Table [2](#T2){ref-type="table"}).

###### 

**Important characteristics of biomarkers for clinical use in acute infections** (**from**\[[@B3]\])

  **Criteria for use**                                                                                                               **Characteristics**
  ---------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnostic test                                                                                                                    General: known preanalytic and analytic (accuracy, reproducibility) as well as physiological (intra and interindividual) variability, integrated in the interpretation of assay results
  High predictive values                                                                                                             
  Ability to differentiate sepsis and noninfectious SIRS (specificity)                                                               
  Ability to differentiate acute viral from bacterial infection                                                                      
  Prognostic test                                                                                                                    Early detection of patients at risk of a complicated course
  Levels associated with the inflammatory response (i.e., correlated to the severity of presentation and/or to organ dysfunctions)   
  Predictor of mortality                                                                                                             
  Therapeutic test                                                                                                                   Follow-up of the efficacy of a therapy (e.g., rapid kinetics, independent of organ dysfunction)
  Accessibility                                                                                                                      Routinely available
  Good acceptability to patients (i.e., noninvasive)                                                                                 
  Rapid turnaround time                                                                                                              
  Easily interpreted                                                                                                                 
  Low cost                                                                                                                           

### Potential role of biomarkers in acute infections: performance measurements

Biomarkers are expected to provide an assessment of the severity of infection or predict a complicated course to help making a decision on the best therapeutic approach and appropriate site of care (i.e., hospital or ambulatory care, intensive or ward care). Foremost, they should help the physician to decide about introducing or maintaining antibiotic therapy.

Within the recent years, dozens of potential biomarkers of infection have been described, and their analysis is a complex task. Current trends are to use a combination of biomarkers---notably cytokines---with multiplex tests providing simultaneous measurements of several biomarkers from a single biological sample. The major point is to examine whether their clinical performance and utility can be transposed to acute care situations.

The diagnostic performance of biomarkers is usually measured in terms of sensitivity (probability of a positive test among affected patients), specificity (probability of a negative test in unaffected patients), and by likelihood ratios and area under the ROC (*Receiver Operating Characteristics*) curves. Ideally, a biomarker would be both highly sensitive and specific; however, very sensitive tests provide few false-negative results, whereas highly specific ones provide few false-positive results. In emergency medicine practice, more emphasis is usually put on sensitivity (and negative predictive value, NPV), as the primary objective is to rule out the disease, whereas specificity (or positive predictive value, PPV) is emphasized when the objective is to confirm a clinical diagnosis. For quantitative tests, establishing ROC curves allows to select the best compromise between sensitivity and specificity of the test, according to which approach is emphasized. When a low threshold for positivity of the test is selected, its sensitivity increases but its specificity is lowered.

Sensitivity and specificity are however defined within a population where the patients' status ("infected" or "noninfected") is known, which does not corresponds to the population seen by the physician in his routine clinical practice. The clinical utility of a biomarker is therefore best assessed by measuring its predictive values (both positive and negative, PPV and NPV) and changes between pre- and post-test likelihood ratios in a given clinical context.

Two important points, often overlooked in the literature, should be considered when assessing the operating characteristics of biomarkers:

The characteristics of the population studied and of the "control group" (i.e., noninfected). For example, it is quite different to analyse a group of patients with a systemic inflammatory response (SIRS) following cardiac surgery (where the severity and prevalence of infection is low) or patients with SIRS within the context of pancreatitis evolving since \>1 week, and both the severity and prevalence of infection are higher, with a high clinical impact of diagnosing infected pancreatitis necrosis.

Criteria used as the "gold standard" for defining infection (or lack thereof) \[[@B4],[@B5]\].

Limitations to the interpretation of biomarker levels
-----------------------------------------------------

Improved measurement methods have largely enhanced the potential for biomarkers to identify patients at high risk of death or a complicated course, whether individual patients or the general population. Nevertheless, persisting difficulties arise when interpreting measurements of biomarker levels, a problem that is compounded by the dissemination of multiplex tests \[[@B6]\], thus increasing the volume of information generated. For some biomarkers, a threshold value can be determined, which allows a simple binary interpretation, but inevitably results in loss of precision; however, this approach cannot be generalised.

Interpreting biomarker levels can be problematic because of the variability of measurements resulting from several factors:

A lack of standardisation between different methods,

Biological factors, including preanalytical variables (tubes and transport media, time from sampling to analysis, etc.), analytical (precision, reproducibility, threshold of measurement, etc.), and intra- or interindividual variations; such factors must be assessed and controlled for before providing an interpretation of assays results.

In addition, prudent interpretation is mandatory when the known sensitivity or specificity of the biomarker measured is \<90% or when the number of subjects studied is small. Moreover, in many studies, a single point in time has been obtained for biomarker measurement, and the lack of repeated measurements does not allow the use of such marker for adapting the duration of therapy.

We conclude that standardisation of measurement methods and guideline for the interpretation of biomarker levels in acute infections is mandatory before introducing their measurements into clinical practice. This development phase, including the determination of associated quality criteria (i.e., reproducibility and variation coefficient, threshold for detection), identification of confounding factors and corrective factors must be investigated. Finally, medico-economic evaluation is usually lacking and should be performed before proposing their introduction into routine clinical use.

Biomarkers currently available for optimising antibiotic therapy
----------------------------------------------------------------

More than a hundred biomarkers have been studied in the serum of septic patients \[[@B7]-[@B9]\]. Few of them however are eligible for entering the clinical arena (see Additional file [1](#S1){ref-type="supplementary-material"}: Table S1) and being used for optimising antibiotic therapy because of limitations to the interpretation of results from these studies. Assays used often are not standardised (especially for ELISA and "multiplex" tests), making it difficult to compare results from different studies. Some techniques are difficult to adapt to the emergency context (multiplex tests, ELISA or high-flux cytometry). Some biomarkers cannot be presently retained because of a poor performance, of studies limited to a small population (e.g., \<50 patients) or too scarce to allow conclusions on their potential utility. A limited number of biomarkers are currently of established or potential clinical interest within the field of acute infection.

### Routinely available biomarkers

Two biomarkers fulfill the selection criteria mentioned above and are routinely available: C-Reactive protein (CRP) and procalcitonin (PCT). CRP has been tested in various conditions, but only a few of these studies have focused on its use for optimising antibiotic therapy. A single, prospective, randomized, controlled trial performed in the 1990s in children is available \[[@B10]\]; other studies have compared an intervention group to historical controls \[[@B11],[@B12]\]. Despite the few available studies confirming its usefulness, CRP measurements are widely used in children to adjust the duration of therapy. Several studies are ongoing, testing the usefulness of CRP measurements as an aid to shorten the duration of therapy in adult patients having sepsis, community-acquired pneumonia or exacerbation of chronic obstructive pulmonary disease (COPD). Pending results from these studies, the use of CRP cannot be recommended at present as an aid to the initiation or discontinuation of antibiotics in adults; in children, however, CRP can probably be used to help discontinuing therapy, although the evidence is limited.

Procalcitonin has been more widely tested for optimising antibiotic therapy in both children and adults. In adults presenting with community-acquired lower respiratory tract infections (LRTI), several randomized, controlled trials (RCTs) have tested the use of PCT as an aid to the initiation and/or discontinuation of antibiotics and have been summarised in a recent individual patient meta-analysis \[[@B13]-[@B17]\]. Four of these studies enrolled more than 900 patients hospitalised in intensive care or high-dependency units \[[@B18]-[@B21]\]. Two well-designed studies have been performed in children: one study included 121 neonates having early sepsis \[[@B22]\] and another studied 384 children aged 1 to 36 months with acute fever of undetermined origin (Manzano, Bailey et al. 2010; Esposito, Tagliabue et al. 2011).

In view of these studies, the inclusion of PCT measurements within decision algorithms of antibiotic management for specific infections is likely appropriate (refer to Part II). However, further studies are needed in infections which have been insufficiently examined so far (i.e., most infections other than LRTI) to better define the role of PCT in the antibiotic strategy.

### Recent biomarkers of potential interest in the near future

Intensive efforts are being made in the search of new diagnostic and prognostic biomarkers, which may be helpful for the management of antibiotic therapy in acute infections. In adults, four of these, the soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1), Soluble urokinase-type Plasminogen receptor (suPAR), proadrenomedullin (ProADM), and Presepsin appear promising. These four biomarkers are of reasonably easy access, have demonstrated acceptable sensitivity and/or specificity, and have been studied in a substantial number of patients to merit further consideration in adults. In children or neonates, too few and heterogeneous studies have been conducted with these new biomarkers to allow recommending any of these for potential introduction in the clinical arena at the present time; further studies are needed in these age groups.

#### sTREM-1

A member of the immunoglobulin superfamily, TREM-1 is a surface receptor of mature polymorphonuclear and monocytes cells contributing to innate immunity. Its expression is up-regulated when phagocytic cells are exposed to bacterial and fungal pathogens, but not during other non-septic inflammatory processes. TREM-1 amplifies the inflammatory response by increasing the production of pro-inflammatory cytokines while inhibiting IL-10 synthesis. During up-regulation of the surface receptor TREM-1, the soluble form sTREM-1 increases in biological fluids (blood, broncho-alveolar lavage fluid, CSF), where it can be assayed by ELISA using commercial immunoassay kits.

Several clinical studies \[[@B23]-[@B29]\] have tested the diagnostic and prognostic value of sTREM-1 (Table [3](#T3){ref-type="table"}). Measurements in samples taken at the site of infection (CSF, BAL, pleural fluid) appear of higher clinical significance than plasma measurements.

###### 

**Clinical experience with the use of sTREM**-**1 in acute infections**

  **sTREM**-**1**    **References**                        **Syndrome/disease studied**                **Sampling**
  ------------------ ------------------------------------- ------------------------------------------- --------------
  Diagnostic value   \[[@B23]\]                            Pneumonia                                   Plasma
  \[[@B24]\]         Pneumonia                             BAL                                         
  \[[@B25]\]         Meningitis                            CSF                                         
  \[[@B26]\]         Meningitis                            CSF                                         
  Prognostic value   \[[@B27]\]                            SIRS, sepsis, severe sepsis, septic shock   Plasma
  \[[@B28]\]         Sepsis, severe sepsis, septic shock   Plasma                                      
  \[[@B29]\]         Sepsis, septic shock                  Plasma                                      

#### suPAR

suPAR (soluble urokinase-type plasminogen activator receptor) or CD87 is a widespread receptor for inflammatory response. Its constitutive expression is limited to some cell types, such as endothelium and leucocytes (polymorphonuclear, monocytes/macrophages). Its gene expression is under control of immune and inflammatory effectors, such as bacterial products (LPS), cytokines (IFN-gamma, TNF-alpha, IL-1-beta), and growth factors (FGF-2, VEGF, TGF-beta, EGF). During the inflammatory and immune response, the expression of suPAR is up-regulated on epithelial cells, leucocytes (lymphocytes), smooth muscle cells and fibroblasts; it also is up-regulated during tumour growth and metastatic tumour dissemination. Measurements can be obtained from commercial ELISA kits; suPAR measurements also are included in multiplex assays together with cytokines.

suPAR is of limited value as a diagnostic test. Its clinical value appears associated with its ability to identify patients at risk (Table [4](#T4){ref-type="table"}) and might be of interest for the management of HIV patients receiving antiretroviral therapy \[[@B30]\], during the follow-up of patients who have nonpulmonary mycobacterial infection \[[@B31]\] and in children who have *Plasmodium falciparum* malaria \[[@B32]\]. suPAR also might be useful for the management of antibiotics in patients with sepsis \[[@B33]-[@B35]\], but this approach needs more extensive evaluation.

###### 

Clinical experience with the use of suPAR in acute infections

  **suPAR**                                        
  ------------------ ------------------- -------- --------
  Diagnostic value   \[[@B33],[@B34]\]   Sepsis   Plasma
  Pronostic value    \[[@B33]-[@B35]\]   Sepsis   Plasma

#### Pro-ADM

Adrenomedullin (ADM) is a 52-amino acids peptide, and a marker of the *CALC* gene family, acting as a mediator of cell proliferation, hormone regulation and embryogenesis. ADM is produced by endothelial cells, where it induces vasodilatation and maintains homeostasis. Pro-hormone fragments (pro-ADM) are more stable than the complete peptide and their levels can be measured in biological fluids by automated methods using the TRACE (Time-Resolved Amplified Cryptate Emission) method after immuno-capture. ProADM secretion increases during the immune response to viral or bacterial products in relation to the importance of the stimulation.

Pro-ADM is a biomarker of prognostic value (Table [5](#T5){ref-type="table"}). Added to a clinical pneumonia severity score \[[@B36]\], pro-ADM could be used to identify the more severe patients for close monitoring and/or needing ICU care \[[@B37]-[@B40]\].

###### 

Clinical experience with the use of pro-ADM in acute infections

  **proADM**                                          
  ------------------ ------------------- ----------- --------
  Diagnostic value   \-                  \-           
  Prognostic value   \[[@B38]-[@B40]\]   Pneumonia   Plasma

#### Presepsin

Presepsin (formerly CD14), is a glycoprotein receptor occurring at the surface of monocytes/macrophages. CD14 binds to lipopolysaccharide (LPS) complexes and LPS binding protein (LPB), which triggers the activation of toll-like receptor 4 (TLR4), resulting in the production of numerous pro-inflammatory cytokines. Following Presepsin activation by bacterial products, the CD14 complex is released in the circulation as its soluble form (sCD14), which in turn is cleaved by a plasma protease to generate a sCD14 fragment called sCD14-subtype (sCD14-ST). Plasma levels of sCD14 can be measured using an automated chemo-luminescent assay (PATHFAST®, Ingen®, France).

The most recent of the 4 biomarkers analysed, presepsin is both sensitive and specific and might be helpful to differentiate SIRS from sepsis associated with a bacterial infection \[[@B41]-[@B43]\] (Table [6](#T6){ref-type="table"}).

###### 

Clinical experience with the use of Presepsin in acute infections

  **Presepsin**                                                           
  -------------------- ------------------- ----------------------------- --------------
  **Clinical value**   **References**      **Syndrome/disease**          **Sampling**
  Diagnostic value     \[[@B41],[@B42]\]   SIRS, Sepsis                  plasma
  Pronostic value      \[[@B43]\]          SIRS, Sepsis, Severe sepsis   plasma

We conclude that information gathered so far on these four biomarkers--- sTREM-1, suPAR, proADM, and presepsin---suggest that they may have a role in future clinical developments, whether as diagnostic tests, or for stratification of patients by type of insult or severity, or to assess the therapeutic activity and efficacy and during follow-up of patients. To date, there are too few studies of the impact of these new biomarkers on the antibiotic management of patients and larger studies are required in this field.

Future developments
-------------------

Micro-RNAs (miR) are recently discovered potential candidate biomarkers. miR are small molecules (about 20 nucleotides) present in eucaryotic cells, which act as biologic regulators by modulating posttranscriptional regulation. They are ubiquitous and abound in the lung, liver, and kidney. After binding the corresponding smRNA sequence, they regulate gene expression by a repressor effect or by altering its target. A mi-RNA can bind to several smRNA. Their expression can be measured by RT-PCR and quantitative PCR.

Their multiple potential roles in positive or negative regulation of gene expression have been uncovered since the early 2000s, and dysfunctions of miR expression have been implicated in numerous human diseases (<http://www.miR2Disease.org/>), such as various types of cancers ("oncomir"), cardiomyopathy, or central nervous system diseases. miR also have been implicated in defense mechanisms against viral infections, where they may contribute to controlling viral infections. Integrated in the viral genome, a number of miR can regulate viral mRNA such as Epstein-Barr, cytomegalovirus, herpes, hepatitis C virus as well as the host's RNA. Among bacterial infections, a role for miR has been suggested in *M*. *tuberculosis* infections by modulating the monocytes/macrophages interactions with the bacterium or regulating the expression of resistance gene or virulence factors. Modulation of the inflammatory response to infection with *H*. *pylori* also has been attributed to miR \[[@B44]\], notably miR-155 \[[@B45]\].

The spectrum of miRNAs initially released in blood and leucocytes of patients with septic shock differs from that of control patients. The three most dysregulated miR are miR-150, miR-182, miR-342-5p; miR-150 interferes with the development of an immune response by lymphocytes and thus might be a potential candidate as an early diagnostic and/or prognostic marker \[[@B46]\].

Other miRNAs have been associated with a high probability of a poor outcome in patients with septic shock: miR-223, miR-15a, miR-16, miR-122, miR-193\*, and miR-483-5p. Based on individual AUROC for each miR, prediction of death varied between 0.61 (95% confidence interval (CI) 0.523-0.697) and 0.79 (95% CI 0.719-0.861) but reached 0.953 (95% CI 0.923-0.983) when combining the seven parameters \[[@B47]\].

Thus, miR might be potential candidates as early diagnostic and/or prognostic markers in sepsis. Numerous studies are needed with these new markers to better understand their role in biochemical and immunobiology processes in humans before their use for diagnostic and stratification of patients, prognostication, or therapeutic decision can be considered.

Two main technological advances are in progress, including 1) the development of point-of-care testing, with the availability of miniaturised and portable machines, allowing rapid testing at the bedside, even for sophisticated measurements (e.g., flux cytometry), which have been confined to specialised laboratories up to recently; and 2) the development of new methods, including the analysis of gene expression (genomics), of ARN activation (transcriptome), of production of proteins (proteomics), of lipids (lipidomics), or of metabolites (metabolomics). It is likely that these progresses will allow identifying new markers for better identification of patients, stratification of prognosis, and targeting therapy.
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